A majority of patient deaths within two years of TAVR can be linked to cardiovascular complications, according to new research published in JACC: Cardiovascular Interventions. Can follow-up care be improved to combat this trend? 

Asking patients to use smartphone-powered ECG devices following catheter ablation procedures could be incredibly beneficial, according to new findings published in JACC: Clinical Electrophysiology. 

“Many within the healthcare industry believe that cardiovascular care will be increasingly delivered in non-traditional ambulatory settings,” according to one author. “The cardiovascular care community must consider and prepare for this eventuality."

American College of Cardiology President B. Hadley Wilson, MD, discussed why the ACC and other leading cardiology groups are so eager to create a new, independent medical board. This has been a long-term goal for many years, he said, and now it may become a reality. 

"We know that the cardiovascular community is ready for an independent, self-governed entity, and we are proud to develop this new board with cardiologists and cardiology organizations at the helm," ACC President B. Hadley Wilson, MD, said in a statement.

New research in JACC: Cardiovascular Interventions explored the potential of performing EP studies before and after valve deployment. TAVR operators handled all catheter manipulations, and EP specialists were on hand to capture the necessary measurements. 

The ACC has joined forces with Amgen and Esperion Therapeutics to increase LDL screening in patients with and without a history of cardiovascular issues.

Researchers explored data from more than 2,300 patients, categorizing all bleeding events based on updated VARC-3 definitions. The team's final analysis was published in JACC: Cardiovascular Interventions.